Verastem Oncology VS-7375 R&D Update - VERASTEM INC

Explicit Guidance:

• Clinical Trial Accrual & Data Readouts:
  • Expect accrual for Pancreatic (PDAC) and Colorectal (CRC) Phase 2 accelerated approval trials to finish by end of 2024.
  • Expect accrual for Lung Cancer Phase 2 trial to finish in the first half of 2025.
  • Anticipate receiving updated data for the CRC cohort and 600mg Pancreatic combination (with Gemcitabine/Nab-paclitaxel) by end of 2024; expect broader combo data (including 900mg + EGFR) by the first half of 2025.
• Regulatory Milestones:
  • Phase 3 (PDAC): The "301" frontline study is expected to open by end of 2024.
  • Phase 3 (Lung & CRC): The "302" (Lung) and "303" (CRC) frontline studies are expected to open in the first half of 2025.
  • Accelerated Approval Strategy: Potential to submit for accelerated approval in frontline PDAC based on Overall Response Rate (ORR) alone after enrolling 240 patients (two-thirds of the 360 planned), leveraging FDA "Front Runner" program logic.

Business-Segment Outlook:

• Pancreatic Cancer (PDAC):
  • Current Status: In second-line and later settings, the drug demonstrates unprecedented activity with 2 confirmed Complete Responses (CRs) in 22 patients; PFS has crossed 6.5 months (exceeding the 4.3-month benchmark of competitors) and is trending toward the 7.5-month second-line benchmark.
  • Frontline Goal: Aim to establish the drug as the standard of care in the first-line setting to treat the largest patient population at the point of greatest susceptibility.
  • Combination Strategy: Proceeding with safety studies for combinations with Anti-EGFR agents (Cetuximab) and standard chemotherapy (Gem/Nab, modified FOLFIRINOX).
• Colorectal Cancer (CRC):
  • Current Status: Phase 2 trial enrolling; early data shows PFS exceeding 5.6 months (benchmark for Lonsurf + Avastin) and ORR in the ~30% range.
  • Frontline Goal: Developing a randomized Phase 3 study utilizing the combination of Anti-EGFR + modified FOLFIRI + VS-7375.
• Lung Cancer (NSCLC):
  • Current Status: At 600mg, confirmed ORR is 43%, with responses occurring rapidly (at first scan) and showing high durability.
  • Frontline Potential: Moving to evaluate 900mg in combination with chemo-immunotherapy; early frontline data (600mg + Keytruda) shows a 75% ORR.
• Product Differentiation:
  • Dose Optimization: Go-forward dose established at 900mg for Pancreatic and CRC (vs. 600mg for Lung Phase 2); 900mg delivers superior PK/AUC and deeper tumor responses with an identical safety profile to 600mg.
  • Durability: Expectation of indefinite treatment duration without cumulative toxicity, contrasting with the ~3-month limits of standard chemotherapy.

Market and Competitive Outlook:

• Competitive Landscape:
  • VS-7375 vs. Others: Positions as "best-in-class" based on higher tumor penetration (80%+ of patients achieve >2000 AUC) and confirmed response rates (50% in 2L PDAC vs. 24% for Adagrasib; 36% in 3L+ vs. ~21% for Adagrasib).
  • Differentiation: Superior tolerability (Grade 1-2 GI AEs only; no Grade 4/5 events in monotherapy) compared to Pan-RAS inhibitors (e.g., Adagrasib) which face dose-limiting toxicities (rash, diarrhea, mucositis).
  • Response Profile: Unique ability to achieve "pure waterfalls" (tumor shrinkage in nearly all patients) and molecular clearance (VAF elimination in ~60% of patients).
• Future Treatment Paradigm:
  • Post-Progression Management: Envisioning a shift to treating patients "on progression" via local therapies (radiation, ablation) while maintaining systemic drug therapy, rather than immediate discontinuation.
  • Combination Potential: High potential for dual targeting (e.g., G12D + PRMT5 inhibitors for MTAP-deleted tumors) and G12D + EGFR.

Macro / Industry Outlook:

• Regulatory Environment: FDA has granted unique approval design elements for Phase 3 PDAC trials, including the inclusion of Overall Response Rate (ORR) as a co-primary endpoint and the ability to move Overall Survival (OS) to a secondary endpoint due to cross-over provisions.
• Patient Access: FDA has recognized the drug's unique qualities, allowing for expedited pathways (Front Runner program) to potentially win approval in the frontline setting earlier than standard PFS-driven trials.

Strategic Initiatives:

• Dosing & Formulation:
  • Dose Escalation: Shifted from 600mg to 900mg go-forward dose based on linear PK and lack of increased toxicity.
  • Formulation Development: Developing a new formulation (tested in dogs) to eliminate GI side effects (vomiting) entirely; early animal data shows 0% vomiting compared to the current formulation.
• Expansion of Indications:
  • Adjuvant/Neoadjuvant: Exploring use in earlier disease stages (adjuvant, neoadjuvant, maintenance) and potentially in cystic precursors (IPMN) to intercept cancer development.
  • Combination Partners: Actively testing and expanding data on combinations with Anti-EGFR, PRMT5 inhibitors (e.g., Defactinib), and Pan-RAS inhibitors (Erasca).
• Geographic Expansion:
  • Global Phase 3: Plans for international Phase 3 trials; engaging with European regulators (EMA) for similar design acceptance, though acknowledging potential regulatory hurdles regarding OS endpoints.
• Financial Position:
  • Capital Raise: Recent financing extends runway into 2028, covering Phase 2 readouts.
  • Commercialization Strategy: Open to partnering to scale commercialization and add expertise, retaining upside while leveraging partner resources; CEO emphasizes "partnerships make the pie bigger."

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Success is contingent on FDA acceptance of ORR as a primary endpoint for accelerated approval in the frontline setting; European regulators may be less comfortable with OS as a secondary endpoint.
• Resistance Mechanisms: Emerging data suggests progression may occur via single-lesion outgrowth (clonal evolution); requires investigation into resistance mechanisms and potential need for future combination therapies.
• Clinical Trial Execution: Fast enrollment rates in Phase 2 (some cohorts full) and the complexity of designing large-scale frontline trials with cross-over provisions.
• Combination Toxicity: While currently clean, adding multiple agents (e.g., Pan-RAS + G12D) carries theoretical risks of overlapping toxicity that must be managed.

Management Tone on the Future:

• Confidence Level: Extremely high ("best-in-class," "game-changing," "miracle," "stupendous"). Management expresses strong conviction that the drug's tolerability and efficacy profile will allow it to replace current standard-of-care chemotherapies.
• Vision: A shift from "death sentences" to long-term disease control (2-3+ years survival) and a potential future where selective RAS inhibitors are used for cancer interception/prevention.
• Strategic Shift: Moving from skepticism (FDA's initial view) to collaboration; management emphasizes agility and speed in execution compared to larger biotech peers.
• Patient-Centricity: Strong emphasis on Quality of Life (QoL) and pain relief as immediate differentiators, with a belief that tolerability will drive long-term adherence and disease suppression.

Miscellaneous:

• Pre-Clinical Validation: Mice models accurately predicted human PK and efficacy; dogs showed 0% vomiting with the new formulation.
• Molecular Monitoring: CA-19-9 trends correlate well with response; VAF (variant allele frequency) is a validated early marker of efficacy.
• Safety Dynamics: GI AEs are transient; ~25% of patients have no GI AEs in Cycle 1, increasing to ~40% by 6 months, allowing for dose intensity maintenance.